Tavares et al. studied the role of HDAC6 in cisplatin-resistant HNSCC by inhibiting HDAC6 with tubastatin A. They reported that HDAC6 was increased in cisplatin-resistant HNSCC and that treatment with tubastatin A overcame cisplatin resistance, in monotherapy and in combination with cisplatin [224]. Here, HDAC6 is linked to head and neck squamous cell carcinoma.